Acrivon Therapeutics (ACRV)
Develops cancer therapies and companion diagnostics around drug-specific proteomic patient selection.
$2.15
Pre-market−0.00 (−0.23%)
At close$2.16(+4.11%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions43 holders · as of Mar 31, 2026 | 37.89% | 16.24M shares | |
| Insiders15 holders · as of Sep 2, 2026 | 7.31% | 3.13M shares | |
| Otherremainder | 54.80% | 23.49M shares |
42.85M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Institutions13F, as of Mar 31, 2026
43 holders · 16.24M shares · 10 new positions · 21 increased · 10 reduced · 15 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 8.34M | 19.46% | 0 | May 15, 2026 |
| Sands Capital Ventures, LLC | 2.12M | 4.95% | 0 | May 8, 2026 |
| Wellington Management Group LLP | 888.1K | 2.07% | 0 | May 15, 2026 |
| Acadian Asset Management LLC | 846.0K | 1.97% | +264.8K | May 13, 2026 |
| Renaissance Technologies LLC | 758.4K | 1.77% | +124.3K | May 14, 2026 |
| Vanguard Capital Management LLC | 722.0K | 1.68% | +722.0Knew | May 15, 2026 |
| Marshall Wace, LLP | 560.4K | 1.31% | +64.4K | May 15, 2026 |
| Two Sigma Investments, LP | 389.4K | 0.91% | −195.7K | May 15, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Peter Kolchinskyincl. RA Capital Management, L.P., Rajeev Shah +1 more | 28.80% | 12.28M | 13D | Apr 23, 2026 ↗ |
| Sands Capital Life Sciences Pulse Fund II, L.P. | 6.80% | 2.12M | 13G | Aug 13, 2025 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 25, 2026 | Peter Blume-Jensendirector, officer: President and CEO | Sale | 14,036 | $2.21 | 2,230,052 |
| Aug 18, 2026 | Erick Gamelinofficer: Chief Development Officer | Sale | 400 | $2.01 | 52,592 |
| Aug 18, 2026 | Mary Millerofficer: Chief Legal Officer | Sale | 185 | $2.01 | 82,009 |
| Aug 18, 2026 | Katharine Petersonofficer: Chief Accounting Officer | Sale | 101 | $2.01 | 18,033 |
| Aug 18, 2026 | Peter Blume-Jensendirector, officer: President and CEO | Sale · 2 lots | 1,713 | $2.01 | 2,629,947 |
| Aug 18, 2026 | Eric Devroeofficer: Chief Operating Officer | Sale | 604 | $2.01 | 146,349 |
| Aug 4, 2026 | Adam D. Levyofficer: Chief Financial Officer | Sale | 1,142 | $1.57 | 66,008 |
| Jul 21, 2026 | Mary Millerofficer: Chief Legal Officer | Sale | 573 | $1.76 | 82,194 |
| Jan 14, 2026 | Adam D. Levyofficer: Chief Financial Officer | Purchase | 8,832 | $1.70 | 20,983 |
| Jan 14, 2026 | Peter Blume-Jensendirector, officer: President and CEO | Purchase | 49,000 | $1.68 | 2,095,771 |
CongressHouse and Senate disclosures
Not reported.